Literature DB >> 26931474

Communication from Tubular Epithelial Cells to Podocytes through Sirt1 and Nicotinic Acid Metabolism.

Kazuhiro Hasegawa1, Shu Wakino, Yusuke Sakamaki, Hirokazu Muraoka, Hiroyuki Umino, Hitoshi Minakuchi, Ayumi Yoshifuji, Makiko Naitoh, Keisuke Shinozuka, Koji Futatsugi, Hidenori Urai, Takeshi Kanda, Hirobumi Tokuyama, Koichi Hayashi, Hiroshi Itoh.   

Abstract

We have recently published that tubular epithelial cells affect the podocyte epigenome though nicotinic acid metabolism in diabetic nephropathy (DN), and we have named this relationship "proximal tubule-podocyte communication". In this review, we describe this novel mechanism in the early stage of DN, focusing on the function of renal tubular Sirt1 and Sirt1-related nicotinic acid metabolism. Mainly, we discuss the following three findings. First, we described the details of proximal tubule-podocyte communication. Second, we explained how Sirt1 regulates albuminuria via epigenetic mechanisms. This means that repeated high glucose stress triggers the initial changes in proximal tubules, which lead to the epigenetically irreversible glomerular damages. However, proximal tubular Sirt1 overexpression can rescue these changes. Our previous data indicated that the decrease in Sirt1 expression in proximal tubules caused the reduction in glomerular Sirt1 and the subsequent increase in glomerular Claudin-1. It seemed plausible that some humoral mediator is released from proximal tubules, migrates to podocytes and glomeruli, and affects Sirt1 expression in podocytes. Third, we mentioned a mediator connecting this communication, nicotinamide mononucleotide (NMN). We suggest the potential of Sirt1 or NMN as not only a therapeutic target but also as a prognostic marker of very early stage DN.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26931474     DOI: 10.2174/1573402112666160302102217

Source DB:  PubMed          Journal:  Curr Hypertens Rev        ISSN: 1573-4021


  7 in total

Review 1.  Histone Deacetylases Take Center Stage on Regulation of Podocyte Function.

Authors:  Min Liu; Zhe Qiao; Yang Zhang; Ping Zhan; Fan Yi
Journal:  Kidney Dis (Basel)       Date:  2020-04-29

2.  Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy.

Authors:  Itaru Yasuda; Kazuhiro Hasegawa; Yusuke Sakamaki; Hirokazu Muraoka; Takahisa Kawaguchi; Ei Kusahana; Takashi Ono; Takeshi Kanda; Hirobumi Tokuyama; Shu Wakino; Hiroshi Itoh
Journal:  J Am Soc Nephrol       Date:  2021-04-01       Impact factor: 14.978

Review 3.  Novel tubular-glomerular interplay in diabetic kidney disease mediated by sirtuin 1, nicotinamide mononucleotide, and nicotinamide adenine dinucleotide Oshima Award Address 2017.

Authors:  Kazuhiro Hasegawa
Journal:  Clin Exp Nephrol       Date:  2019-03-11       Impact factor: 2.801

4.  Renal tubular Bim mediates the tubule-podocyte crosstalk via NFAT2 to induce podocyte cytoskeletal dysfunction.

Authors:  Chunmei Xu; Xiaojun Zhou; Tianyue Xie; Yuan Zhou; Qian Zhang; Shan Jiang; Rui Zhang; Lin Liao; Jianjun Dong
Journal:  Theranostics       Date:  2020-05-22       Impact factor: 11.556

5.  Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction.

Authors:  Saeko Sato; Kaori Takayanagi; Taisuke Shimizu; Takatsugu Iwashita; Koichi Kanozawa; Hajime Hasegawa
Journal:  Eur J Med Res       Date:  2022-08-06       Impact factor: 4.981

6.  TFP5-Mediated CDK5 Activity Inhibition Improves Diabetic Nephropathy via NGF/Sirt1 Regulating Axis.

Authors:  Shi-Lu Cao; Hong-Yan Luo; Yong-Cai Gao; Xiao-Mei Lan; Shun-Yao Liu; Bo Li; Li Bao; Jing E; Danna Ma; Guo-Qing Zhang; Li-Rong Yang; Xi Bao; Ya-Li Zheng
Journal:  Front Cell Dev Biol       Date:  2022-07-07

Review 7.  Role of sirtuin-1 in diabetic nephropathy.

Authors:  Wanning Wang; Weixia Sun; Yanli Cheng; Zhonggao Xu; Lu Cai
Journal:  J Mol Med (Berl)       Date:  2019-02-01       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.